Skip to main content
Clinical Trials/NCT01298128
NCT01298128
Terminated
Not Applicable

A Randomized Controlled Trial of NuvaRing® Versus Combined Oral Contraceptive Pills for Pre-treatment in In-Vitro Fertilization (IVF) Cycles

University of Toronto0 sites70 target enrollmentFebruary 2006

Overview

Phase
Not Applicable
Intervention
marvelon
Conditions
Infertility
Sponsor
University of Toronto
Enrollment
70
Primary Endpoint
Incidence of Side Effects of Oral Contraceptives Such as Abnormal Bleeding, Headache, Breast Discomfort, Bloating and Mood Swings (See Description)
Status
Terminated
Last Updated
13 years ago

Overview

Brief Summary

The newly designed contraceptive ring, Nuvaring has a lower total steroid dose, and medications are delivered locally. It has been proven to be as safe and effective as the combined OCP in ovarian suppression and preventing ovulation with fewer side effects due to minimal systemic absorption. Following a single vaginal insertion, steroid concentrations remain stable for up to 4 weeks. It is hypothesized that Nuvaring may, therefore lead to better compliance, tolerability and acceptance by patients requiring ovarian suppression prior to COH for IVF.

Registry
clinicaltrials.gov
Start Date
February 2006
End Date
December 2010
Last Updated
13 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Kimberly Liu

Physician

University of Toronto

Eligibility Criteria

Inclusion Criteria

  • Patients less than 38 years of age.
  • Healthy women starting their first IVF/ICSI cycle.
  • No contraindication to Combined Oral Contraceptive (COC) use. Appendix 1
  • Consent to randomization.

Exclusion Criteria

  • Any contraindication to COC use.
  • Hypersensitivity to Nuva ring or any of its components.
  • Language barrier to consent.

Arms & Interventions

Combined oral contraceptive pill

OCP for IVF pre-treatment

Intervention: marvelon

NuvaRing

NuvaRing for IVF pre-treatment

Intervention: NuvaRing

Outcomes

Primary Outcomes

Incidence of Side Effects of Oral Contraceptives Such as Abnormal Bleeding, Headache, Breast Discomfort, Bloating and Mood Swings (See Description)

Time Frame: patients were followed for the duration of an in-vitro fertilization cycle- 2 months

abnormal bleeding, intermittent bleeding, headache, breast discomfort, bloating, mood swings, nausea, vaginal discharge, vomitting, weight gain

Similar Trials

Not yet recruiting
Not Applicable
A randomized controlled trial comparing paracervical block with a combination of paracervical block and fundal anesthesia during endometrial ablation in the outpatient clinic.Endometrial ablationNovasureLocal anesthesiaParacervical blockFundal blockEndometriumablatieNovasureLokale anesthesieParacervicaal blockFundusblokkade
NL-OMON26448Máxima Medisch Centrum, Veldhoven96
Completed
Not Applicable
A randomized controlled trial comparing paracervical block with a combination of paracervical block and fundal anesthesia during endometrial ablation in the outpatient clinic.10029903pain during active endometrial ablation
NL-OMON43705Maxima Medisch Centrum84
Not yet recruiting
Not Applicable
Total Hip joint Arthroplasty: steristrips vs skin glue for skin apposition. A randomised controlled trial.Hip Osteoarthritis requiring total hip joint replacementSkin closure in total hip joint arthroplasty proceduresMusculoskeletal - OsteoarthritisSurgery - Surgical techniques
ACTRN12614000021673Hutt Valley District Health Board180
Completed
Not Applicable
Comparison of the cryopreservation method for day 3 embryos using slow freezing or vitrificatio
ISRCTN16672665Research Foundation Flanders (Belgium)306
Active, not recruiting
Phase 1
Dose reduction and withdrawal of TNF inhibitors in patients with Psoriatic Arthritis and Axial SpondyloarthritisAdults diagnosed with Psoriatic Arthritis en Axial Spondyloarthritis.Therapeutic area: Diseases [C] - Immune System Diseases [C20]
EUCTR2018-003432-72-NLSint Maartenskliniek234